Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Public Health ; 24(1): 1081, 2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38637741

ABSTRACT

BACKGROUND: The prevalence of tobacco use among various cancer types in Iran remains a significant concern, necessitating a comprehensive analysis to understand the extent and patterns of consumption. This study aimed to systematically review and analyze existing literature to delineate the prevalence of tobacco use across different cancer types in Iran, thereby providing a robust basis for future interventions and policy formulations. METHODS: Adhering to the PRISMA guidelines, we conducted a systematic review and meta-analysis of literature available in PubMed and Scopus databases. The initial search identified 351 records, out of which 44 studies were selected based on their relevance and design. These studies spanned various time frames, starting from the 2001s up until 2022, and encompassed diverse geographical locations and cancer types in Iran. To avoid bias and potential data overlap, we opted to incorporate a single comprehensive study from the Golestan Cohort, encompassing all data, while excluding 10 other studies. Our final analysis incorporated data from 34 studies, which accounted for 15,425 patients and 5,890 reported smokers. Statistical analyses were performed to calculate the overall proportion of tobacco consumption and to conduct subgroup analyses based on different variables such as cancer types, gender, geographical locations, and types of tobacco used. RESULTS: The analysis revealed a substantial prevalence of tobacco use among cancer patients in Iran, with an overall consumption rate of 43%. This rate varied significantly, ranging from 10 to 88% across individual studies. Subgroup analyses further highlighted disparities in tobacco consumption rates across different demographics, geographic areas, and cancer types. Notably, the 'ever' smokers category exhibited the highest prevalence of tobacco use. The study also identified a worrying trend of high cigarette smoking rates, along with variable consumption patterns of other forms of tobacco, including waterpipe, 'Naas', and 'Pipe'. CONCLUSIONS: This systematic review and meta-analysis underscores a significant association between tobacco consumption and various cancer types in Iran, with a prevalence rate among cancer patients being three times higher than the average Iranian population. The findings indicate substantial heterogeneity in tobacco use patterns, emphasizing the need for targeted interventions to address this pressing health issue. The study serves as a critical resource for shaping future policies and strategies aimed at curbing tobacco use and mitigating its adverse effects on cancer prevalence in Iran.


Subject(s)
Cigarette Smoking , Neoplasms , Tobacco Use , Humans , Cigarette Smoking/epidemiology , Iran/epidemiology , Neoplasms/epidemiology , Prevalence , Tobacco Use/epidemiology
2.
Prog Biophys Mol Biol ; 187: 51-60, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38373516

ABSTRACT

Neuroblastoma is a common inflammatory-related cancer during infancy. Standard treatment modalities including surgical interventions, high-dose chemotherapy, radiotherapy, and immunotherapy are not able to increase survival rate and reduce tumor relapse in high-risk patients. Mesenchymal stem cells (MSCs) are known for their tumor-targeting and immunomodulating properties. MSCs could be engineered to express anticancer agents (i.e., growth factors, cytokines, pro-apoptotic agents) or deliver oncolytic viruses in the tumor microenvironment. As many functions of MSCs are mediated through their secretome, researchers have tried to use extracellular vesicles (EVs) from MSCs for targeted therapy of neuroblastoma. Here, we reviewed the studies to figure out whether the use of MSCs could be worthwhile in neuroblastoma therapy or not. Native MSCs have shown a promoting or inhibiting role in cancers including neuroblastoma. Therefore, MSCs are proposed as a vehicle to deliver anticancer agents such as oncolytic viruses to the neuroblastoma tumor microenvironment. Although modified MSCs or their EVs have been shown to suppress the tumorigenesis of neuroblastoma, further pre-clinical and clinical studies are required to come to a conclusion.


Subject(s)
Antineoplastic Agents , Extracellular Vesicles , Mesenchymal Stem Cells , Neuroblastoma , Oncolytic Viruses , Humans , Neuroblastoma/therapy , Neuroblastoma/metabolism , Neuroblastoma/pathology , Mesenchymal Stem Cells/metabolism , Extracellular Vesicles/metabolism , Extracellular Vesicles/pathology , Tumor Microenvironment
3.
Cells ; 12(19)2023 09 30.
Article in English | MEDLINE | ID: mdl-37830602

ABSTRACT

Preclinical in vitro models play an important role in studying cancer cell biology and facilitating translational research, especially in the identification of drug targets and drug discovery studies. This is particularly relevant in breast cancer, where the global burden of disease is quite high based on prevalence and a relatively high rate of lethality. Predictive tools to select patients who will be responsive to invasive or morbid therapies (radiotherapy, chemotherapy, immunotherapy, and/or surgery) are relatively lacking. To be clinically relevant, a model must accurately replicate the biology and cellular heterogeneity of the primary tumor. Addressing these requirements and overcoming the limitations of most existing cancer cell lines, which are typically derived from a single clone, we have recently developed conditional reprogramming (CR) technology. The CR technology refers to a co-culture system of primary human normal or tumor cells with irradiated murine fibroblasts in the presence of a Rho-associated kinase inhibitor to allow the primary cells to acquire stem cell properties and the ability to proliferate indefinitely in vitro without any exogenous gene or viral transfection. This innovative approach fulfills many of these needs and offers an alternative that surpasses the deficiencies associated with traditional cancer cell lines. These CR cells (CRCs) can be reprogrammed to maintain a highly proliferative state and reproduce the genomic and histological characteristics of the parental tissue. Therefore, CR technology may be a clinically relevant model to test and predict drug sensitivity, conduct gene profile analysis and xenograft research, and undertake personalized medicine. This review discusses studies that have applied CR technology to conduct breast cancer research.


Subject(s)
Breast Neoplasms , Humans , Mice , Animals , Female , Breast Neoplasms/genetics , Coculture Techniques , Cell Line
4.
Cells ; 12(13)2023 06 24.
Article in English | MEDLINE | ID: mdl-37443748

ABSTRACT

The use of advanced preclinical models has become increasingly important in drug development. This is particularly relevant in bladder cancer, where the global burden of disease is quite high based on prevalence and a relatively high rate of lethality. Predictive tools to select patients who will be responsive to invasive or morbid therapies (chemotherapy, radiotherapy, immunotherapy, and/or surgery) are largely absent. Patient-derived and clinically relevant models including patient-derived xenografts (PDX), organoids, and conditional reprogramming (CR) of cell cultures efficiently generate numerous models and are being used in both basic and translational cancer biology. These CR cells (CRCs) can be reprogrammed to maintain a highly proliferative state and reproduce the genomic and histological characteristics of the parental tissue. Therefore, CR technology may be a clinically relevant model to test and predict drug sensitivity, conduct gene profile analysis and xenograft research, and undertake personalized medicine. This review discusses studies that have utilized CR technology to conduct bladder cancer research.


Subject(s)
Urinary Bladder Neoplasms , Animals , Humans , Disease Models, Animal , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/therapy , Urinary Bladder Neoplasms/pathology , Cell Culture Techniques , Drug Development
5.
Cytokine ; 169: 156248, 2023 09.
Article in English | MEDLINE | ID: mdl-37307689

ABSTRACT

BACKGROUND: One of the regulators in severe acute respiratory syndrome coronavirus2 (SARS-CoV2) infection is miRNAs. In COVID-19 patients, immunological responses to SARS-CoV2 infection may be impacted by miR-155, a miRNA associated to inflammation. MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMCs) of 50 confirmed COVID-19 patients /Healthy Controls (HCs) was isolated by Ficoll. The frequency of T helper 17 and regulatory T cells was analyzed by flowcytometry. The RNA was extracted from each sample and after synthesis of c-DNA, the relative expression of miR-155, suppressor of cytokine signaling (SOCS-1), Signal transducer and activator of transcription 3(STAT3), and Fork Head Box Protein 3 (FoxP3) was evaluated by real-time PCR. The protein level of STAT3, FoxP3 and RORγT in the isolated PBMCs measured by western blotting. The serum level of IL-10, TGF-ß, IL-17 and IL21 was assessed by ELISA method. RESULTS: The population of Th17 cells showed a significant rise, whereas Treg cells reduced in COVID-19 cases. The master transcription factor of Treg (FoxP3) and Th17 (RORγT) relative expression showed the same pattern as flowcytometry. STAT3 level of expression at RNA and protein level increased in COVID-19 cases. FOXP3 and SOCS-1 proteins were down-regulated. The relative expression of miR-155, up-regulated in PBMC of COVID-19 patients and revealed a negative correlation with SOCS-1. The serum cytokine profile showed a reduction in TGF-ß, on the other hand an increase was seen in IL-17, IL-21 and IL-10 in COVID-19 cases toward control group. CONCLUSION: Based on the studies conducted in this field, it can be suggested that Th17/Treg in covid-19 patients can be affected by miR-155 and it can be considered a valuable diagnostic and prognostic factor in this disease.


Subject(s)
COVID-19 , MicroRNAs , Suppressor of Cytokine Signaling 1 Protein , T-Lymphocytes, Regulatory , Th17 Cells , Humans , COVID-19/immunology , COVID-19/metabolism , COVID-19/pathology , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Interleukin-10/metabolism , Interleukin-17/metabolism , Leukocytes, Mononuclear/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , RNA, Viral , SARS-CoV-2/metabolism , Suppressor of Cytokine Signaling 1 Protein/genetics , Suppressor of Cytokine Signaling 1 Protein/metabolism , Suppressor of Cytokine Signaling Proteins/genetics , Suppressor of Cytokine Signaling Proteins/metabolism , T-Lymphocytes, Regulatory/immunology , Th17 Cells/immunology , Transforming Growth Factor beta/metabolism
6.
Pathol Res Pract ; 247: 154558, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37245267

ABSTRACT

Cancer is one of the leading causes of mortality worldwide. Numerous strategies have been developed for cancer treatment. Metastasis, heterogeneity, chemotherapy resistance, recurrence, and evasion of immune surveillance are the primary reasons for the failure of cancer treatment. Cancer stem cells (CSCs) can give rise to tumors via self-renewal and differentiation into various cell types. They show resistance to chemotherapy and radiotherapy and have a strong capability of invasion and metastasis. Extracellular vesicles (EVs) are bilayered vesicles that carry biological molecules and are released under both healthy and unhealthy conditions. It has been shown that one of the leading causes of cancer treatment failure is cancer stem cell-derived EVs (CSC-EVs). CSC-EVs have essential roles in tumor progression, metastasis, tumor angiogenesis, chemoresistance, and immunosuppressants. In the future, controlling EV production in CSCs may be one of the most promising strategies to stop cancer treatment failures.


Subject(s)
Extracellular Vesicles , Neoplasms , Humans , Neoplasms/pathology , Extracellular Vesicles/metabolism , Neoplastic Stem Cells/pathology , Cell Differentiation , Neovascularization, Pathologic/pathology
7.
Cell Commun Signal ; 21(1): 26, 2023 01 30.
Article in English | MEDLINE | ID: mdl-36717861

ABSTRACT

MicroRNAs, as non-coding transcripts, modulate gene expression through RNA silencing under normal physiological conditions. Their aberrant expression has strongly associated with tumorigenesis and cancer development. MiR-20b is one of the crucial miRNAs that regulate essential biological processes such as cell proliferation, apoptosis, autophagy, and migration. Deregulated levels of miR-20b contribute to the early- and advanced stages of cancer. On the other hand, investigations emphasize the tumor suppressor ability of miR-20b. High-throughput strategies are developed to identify miR-20b potential targets, providing the proper insight into its molecular mechanism of action. Moreover, accumulated results suggest that miR-20b exerts its effects through diverse signaling pathways, including PI3K/AKT/mTOR and ERK axes. Restoration of the altered expression levels of miR-20b induces cell apoptosis and reduces invasion and migration. Further, miR-20b can be used as a biomarker in cancer. The current comprehensive review could lead to a better understanding of the miR-20b in either tumorigenesis or tumor regression that may open new avenues for cancer treatment. Video Abstract.


Subject(s)
MicroRNAs , Neoplasms , Phosphatidylinositol 3-Kinases , Humans , Carcinogenesis/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , MicroRNAs/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Neoplasms/genetics
8.
J Family Med Prim Care ; 11(12): 7814-7817, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36994051

ABSTRACT

Background and Aim: Seborrheic dermatitis is a common inflammatory disease for which various treatments have been proposed. The main purpose of this study was to determine the effectiveness of 80-mg Triamcinolone solution diluted with 0.1% normal saline for the treatment of seborrheic dermatitis in adults. Methods: For this study, 120 patients with seborrheic dermatitis were considered. After obtaining written and informed consent, patients were treated with 80 mg of Triamcinolone diluted with 0.1% normal saline. To evaluate the effectiveness of Triamcinolone treatment, the scoring index (SI) and the level of patient satisfaction were evaluated at 2 and 4 weeks after the start of treatment and also 4 weeks after the end of treatment. Results: The results of the study showed that 61.67% (74 patients) were satisfied with "good" to "very good" for the Triamcinolone treatment to seborrheic dermatitis. Based on the findings of the study, it was found that the SI before treatment was equal to 2.45 ± 7.45, which after 2 weeks after treatment, this index decreased by 61.6% (SI: 2.86 ± 1.94). In addition, the SI decreased to 88.6% (SI: 0.85 ± 1.02) after 4 weeks. Conclusion: Considering the high decrease in SI, increasing patient satisfaction and observing a low number of cases with recurrence of the disease by Triamcinolone treatment method, it can be concluded that injection of Triamcinolone 80 mg diluted with 0.1% normal saline can be effective and efficient for the treatment of seborrheic dermatitis.

9.
Neuroscience ; 344: 148-156, 2017 03 06.
Article in English | MEDLINE | ID: mdl-28049030

ABSTRACT

Multiple sclerosis (MS) is an autoimmune disease in which more than 70% of patients experience visual disturbance as the earliest symptoms. Lysolecithin (LPC)-induced focal demyelination model has been developed to evaluate the effects of different therapies on myelin repair improvement. In this study, the effects of pregabalin administration on myelin repair and glial activation were investigated. Local demyelination was induced by administration of LPC (1%, 2µL) into the rat optic chiasm. Rats underwent daily injection of pregabalin (30mg/kg, i.p) or vehicle. Visual-evoked potentials (VEPs) recordings were performed for evaluating the function of optic pathway on days 3, 7, 14 and 28 post lesions. Myelin specific staining and immunostaining against GFAP and Iba1 were also carried out for assessment of myelination and glial activation respectively. Electrophysiological data indicated that pregabalin administration could significantly reduce the P1-N1 latency and increase the amplitude of VEPs waves compared to saline group. Luxol fast blue staining and immunostaining against PLP, as mature myelin marker, showed that myelin repair was improved in animals received pregabalin treatment. In addition, pregabalin effectively reduced the expression of GFAP and Iba1 as activated glial markers in optic chiasm. The present study indicates that pregabalin administration enhances myelin repair and ameliorates glial activation of optic chiasm following local injection of LPC.


Subject(s)
Myelin Sheath/drug effects , Nervous System Autoimmune Disease, Experimental/drug therapy , Neuroglia/drug effects , Neuroprotective Agents/pharmacology , Optic Chiasm/drug effects , Pregabalin/pharmacology , Animals , Calcium-Binding Proteins/metabolism , Demyelinating Autoimmune Diseases, CNS/drug therapy , Demyelinating Autoimmune Diseases, CNS/pathology , Demyelinating Autoimmune Diseases, CNS/physiopathology , Evoked Potentials, Visual/drug effects , Glial Fibrillary Acidic Protein/metabolism , Lysophosphatidylcholines , Male , Microfilament Proteins/metabolism , Myelin Sheath/pathology , Myelin Sheath/physiology , Nervous System Autoimmune Disease, Experimental/pathology , Nervous System Autoimmune Disease, Experimental/physiopathology , Neuroglia/pathology , Neuroglia/physiology , Optic Chiasm/pathology , Optic Chiasm/physiopathology , Random Allocation , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...